# Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer

> **NCT03192735** · PHASE2 · UNKNOWN · sponsor: **Chang-Ming Huang, Prof.** · enrollment: 50 (estimated)

## Conditions studied

- Apatinib Combined
- SOX
- Neoadjuvant Therapy
- Locally Advanced Gastric Cancer

## Interventions

- **DRUG:** ApatinibMesylateTablets

## Key facts

- **NCT ID:** NCT03192735
- **Lead sponsor:** Chang-Ming Huang, Prof.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-09-01
- **Primary completion:** 2019-11-11
- **Final completion:** 2024-12-11
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03192735

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03192735, "Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03192735. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*